iSpecimen financials
$1.23+1.65%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $9.3M | $9.9M | $10.4M | $11.1M |
| Gross profit | $24.1K | $4.0M | $5.1M | $5.6M | $5.9M |
| Gross margin | 1.2% | 42.9% | 51.4% | 54.3% | 52.9% |
| Operating income | -$9.0M | -$12.7M | -$11.2M | -$10.2M | -$5.9M |
| Net income | -$10.5M | -$12.5M | -$11.1M | -$10.2M | -$9.0M |
| Net margin | −543.7% | −134.5% | −111.8% | −98.5% | −80.5% |
| Diluted EPS | $-91.20 | $-703.20 | $-982.00 | $-928.00 | $-1672.00 |
| EBITDA | -$7.2M | -$10.4M | -$9.1M | -$9.0M | -$4.9M |
| Operating cash flow | -$4.2M | -$8.3M | -$5.8M | -$5.8M | -$10.7M |
| Free cash flow | -$4.2M | -$8.3M | -$5.8M | -$6.0M | -$10.7M |
| Diluted shares | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $6.9M | $1.9M | $2.3M | $15.3M | $27.7M |
| Short-term investments | $0.00 | $0.00 | $2.7M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $3.4M |
| Total assets | $9.5M | $9.4M | $15.8M | $24.6M | $35.7M |
| Total liabilities | $6.4M | $6.0M | $6.1M | $4.3M | $5.9M |
| Shareholders' equity | $3.1M | $3.3M | $9.7M | $20.3M | $29.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology